Asian Dividend Stocks Yielding Up To 5.3%
In the current global market landscape, Asian markets are navigating a complex environment marked by trade tensions and economic uncertainties, similar to trends seen in other regions. Amidst these challenges, dividend stocks in Asia can offer a potential source of steady income for investors seeking stability and yield.
Name
Dividend Yield
Dividend Rating
en-japan (TSE:4849)
4.30%
★★★★★★
Wuliangye YibinLtd (SZSE:000858)
5.01%
★★★★★★
Daicel (TSE:4202)
5.00%
★★★★★★
DoshishaLtd (TSE:7483)
4.38%
★★★★★★
CAC Holdings (TSE:4725)
4.86%
★★★★★★
Yamato Kogyo (TSE:5444)
4.68%
★★★★★★
Guangxi LiuYao Group (SHSE:603368)
4.35%
★★★★★★
E J Holdings (TSE:2153)
5.02%
★★★★★★
HUAYU Automotive Systems (SHSE:600741)
4.35%
★★★★★★
Japan Excellent (TSE:8987)
4.42%
★★★★★★
Click here to see the full list of 1253 stocks from our Top Asian Dividend Stocks screener.
We'll examine a selection from our screener results.
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Hanwha Life Insurance Co., Ltd. offers insurance products to both individual and corporate clients in South Korea and internationally, with a market cap of ₩2.13 trillion.
Operations: Hanwha Life Insurance Co., Ltd. generates its revenue from several segments: Insurance (₩21.66 billion), Certificate (₩2.49 billion), Non-financial (₩2.89 billion), and Other Finance (₩203.57 million).
Dividend Yield: 5.3%
Hanwha Life Insurance offers a compelling dividend profile, with its 5.3% yield ranking in the top 25% of Korean dividend payers. Despite only five years of dividend history, payments have been stable and growing with little volatility. The company's dividends are well-covered by earnings (payout ratio: 20.7%) and cash flows (cash payout ratio: 2.5%), indicating sustainability. Additionally, Hanwha Life trades at a significant discount to its estimated fair value, enhancing its attractiveness for value-conscious investors.
Dive into the specifics of Hanwha Life Insurance here with our thorough dividend report.
Upon reviewing our latest valuation report, Hanwha Life Insurance's share price might be too pessimistic.
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Shibaura Mechatronics Corporation, along with its subsidiaries, manufactures and sells equipment for flat panel displays, semiconductors, and electronic components in Japan, Northeastern Asia, and internationally; it has a market cap of approximately ¥103.74 billion.
Operations: Shibaura Mechatronics Corporation generates revenue by producing and selling manufacturing equipment specifically for flat panel displays, semiconductors, and electronic components across Japan, Northeastern Asia, and other international markets.
Dividend Yield: 3.1%
Shibaura Mechatronics' dividend yield of 3.07% is below the top 25% in Japan, and its dividends have been volatile despite recent increases. The company announced a year-end dividend increase to JPY 278 per share for fiscal year 2025 but expects a decrease to JPY 200 for fiscal year 2026. Dividends are well-covered by earnings (payout ratio: 27.1%) and cash flows (cash payout ratio: 78.2%). Despite its unstable dividend history, Shibaura trades at a good value compared to peers.
Unlock comprehensive insights into our analysis of Shibaura Mechatronics stock in this dividend report.
According our valuation report, there's an indication that Shibaura Mechatronics' share price might be on the cheaper side.
Simply Wall St Dividend Rating: ★★★★★☆
Overview: Nireco Corporation operates in Japan, offering process control, web control, and inspection systems, with a market cap of ¥14.35 billion.
Operations: Nireco Corporation generates revenue through its offerings in process control, web control, and inspection systems within Japan.
Dividend Yield: 4.1%
Nireco's dividend yield of 4.08% ranks in the top 25% of Japanese dividend payers, supported by a low payout ratio of 39.1% and a cash payout ratio of 50.6%, ensuring coverage by earnings and cash flows. However, its dividends have been unreliable over the past decade despite recent growth. Nireco plans to repurchase shares worth ¥500 million to enhance capital efficiency, which may influence future dividend stability and value perception among investors.
Click here and access our complete dividend analysis report to understand the dynamics of Nireco.
In light of our recent valuation report, it seems possible that Nireco is trading behind its estimated value.
Explore the 1253 names from our Top Asian Dividend Stocks screener here.
Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSE:A088350 TSE:6590 and TSE:6863.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Tourmaline Oil Corp. (TSE:TOU) Looks Interesting, And It's About To Pay A Dividend
Tourmaline Oil Corp. (TSE:TOU) is about to trade ex-dividend in the next 4 days. The ex-dividend date is usually set to be two business days before the record date, which is the cut-off date on which you must be present on the company's books as a shareholder in order to receive the dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade can take two business days or more to settle. Therefore, if you purchase Tourmaline Oil's shares on or after the 16th of June, you won't be eligible to receive the dividend, when it is paid on the 30th of June. The company's next dividend payment will be CA$0.50 per share, and in the last 12 months, the company paid a total of CA$3.85 per share. Last year's total dividend payments show that Tourmaline Oil has a trailing yield of 6.0% on the current share price of CA$63.81. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. So we need to check whether the dividend payments are covered, and if earnings are growing. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Fortunately Tourmaline Oil's payout ratio is modest, at just 45% of profit. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Over the last year, it paid out more than three-quarters (85%) of its free cash flow generated, which is fairly high and may be starting to limit reinvestment in the business. It's positive to see that Tourmaline Oil's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut. View our latest analysis for Tourmaline Oil Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Businesses with strong growth prospects usually make the best dividend payers, because it's easier to grow dividends when earnings per share are improving. If earnings fall far enough, the company could be forced to cut its dividend. That's why it's comforting to see Tourmaline Oil's earnings have been skyrocketing, up 23% per annum for the past five years. The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Since the start of our data, seven years ago, Tourmaline Oil has lifted its dividend by approximately 43% a year on average. Both per-share earnings and dividends have both been growing rapidly in recent times, which is great to see. Is Tourmaline Oil an attractive dividend stock, or better left on the shelf? From a dividend perspective, we're encouraged to see that earnings per share have been growing, the company is paying out less than half of its earnings, and a bit over half its free cash flow. Overall we think this is an attractive combination and worthy of further research. While it's tempting to invest in Tourmaline Oil for the dividends alone, you should always be mindful of the risks involved. Every company has risks, and we've spotted 2 warning signs for Tourmaline Oil you should know about. A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
Lululemon Athletica Stock (LULU) Plunges 23% as Tariff Pressures Eclipse Earnings Beat
Lululemon Athletica (LULU) shares have declined more than 20% following the release of its quarterly earnings report last week, as investors react to tariff-driven margin concerns and slowing revenue growth. The Canadian athletic apparel brand is beginning to feel the weight of reality in the Trump era following the introduction of sweeping tariffs, while also facing headwinds in its core U.S. market due to tightening discretionary spending and intensifying competition. Confident Investing Starts Here: Several analysts have since lowered their price targets on the stock. Upon closer examination, several underlying trends raise concerns, prompting a cautiously neutral stance. Strong Performance Overshadowed by Margin Concerns in Q1 Despite posting a solid earnings beat for Q1 FY2025, Lululemon (LULU) experienced its steepest single-day drop in years after trimming its full-year EPS guidance by $0.37 per share. While gross margins improved to 58.3% thanks to lower production costs, operating margins slipped 110 basis points to 18.5%, highlighting mounting pressure on profitability. Additionally, comparable store sales grew just 1%, with a 2% decline in the Americas—a concerning trend for the brand's largest market. Notably, it's not just the top-line numbers that tell the story. Lululemon's inventory levels increased 23% versus planned high-teens growth. More and more of its products are collecting dust on its shelves. This could signal demand softness. Lululemon has struggled in the past with its women's apparel aligning with ever-changing trends. How Tariffs Impact the Canadian Apparel Company Though based in Vancouver, Canada, Lululemon is still exposed to the impact of President Trump's tariffs. Like many apparel retailers, the company relies on Asian manufacturing partners in countries such as Vietnam and Indonesia, importing finished goods into key markets, particularly the U.S., which remains its largest. As a result, the renewed import levies are a significant factor behind the company's downward revision to its earnings guidance. Regardless of the troubles the company faces on a macro level, its store count continues to rise as expansion beckons. LULU's Pricing Strategy Faces Risks Amid Consumer Budget Sensitivity Lululemon plans to implement targeted price increases on a select group of products. While this strategy can help support margins, it also carries the risk of dampening demand. After all, Lululemon isn't selling necessities—it's offering premium athletic apparel. In tougher financial climates, price-sensitive consumers may opt to delay purchases or explore more affordable alternatives. A recent Intuit survey found that over 80% of young adults would reduce non-essential spending if economic conditions deteriorate. That puts Lululemon in a position where it must balance profitability with consumer sensitivity. Indeed, other retailers are facing similar challenges, but it's not all negative news for Lululemon. While domestic growth has slowed, the company is seeing strong international momentum. Comparable sales outside the U.S. increased by 6%, with particularly auspicious results in China, where Lululemon ranks as the third-largest foreign sports apparel brand, following Nike and Adidas. Building on this success, Lululemon plans to expand its presence by opening additional stores in China and Europe. In the meantime, other companies competing directly with LULU are shown below. Valuation Still Commands Premium Despite Selloff Perhaps the most significant factor in LULU's volatile stock reaction was the fact that it was priced for perfection. Even after the selloff, Lululemon trades at a Price to Earnings (P/E) ratio of 22.7, which is still a premium relative to its peers in retail. Financially, Lululemon remains in great shape. It generated over $1.5 billion in free cash flow in 2024 and maintains a balance sheet of $1.3 billion in cash and zero debt. Is LULU a Good Stock to Own? On Wall Street, LULU sports a Moderate Buy consensus rating based on 16 Buy, 12 Hold, and two Sell ratings in the past three months. LULU's average stock price target of $313.75 implies ~21% upside potential over the next twelve months. Following its first quarter earnings report, analyst Tom Nikic of Needham lowered his price target on LUL from $366 to $317. Although he believes the selloff was overdone due to the guidance cut being predominantly tariff-driven, he expressed caution over the company's lackluster domestic growth. Moreover, he noted that Lululemon's international comparable growth decelerated, 'raising questions about the growth algo from here.' Randal Konik from Jefferies has a Sell rating on LULU due to slowing growth and increasing competition. On the last point, he notes that the company's attempts to diversify its core offerings have 'not been well-received, leading to lower customer conversion rates.' Lululemon Faces Headwinds Beyond Tariffs Lululemon's challenges can't be attributed solely to President Trump's tariffs. Beyond the impact of import levies on profitability, the company's growth is showing signs of slowing, especially in mature domestic markets. Coupled with a premium valuation and a lowered guidance, these factors contributed to a staggering $8 billion loss in market value. Looking forward, Lululemon must navigate the ongoing tariff pressures alongside intense competition and an American economy marked by consumer uncertainty and inflation. Fortunately, the company has the financial strength to weather these headwinds, and its brand remains strong, especially among younger consumers. That said, the difficulty of protecting profit margins while sustaining high growth in an increasingly competitive athleisure market suggests that investors should approach with caution.
Yahoo
3 hours ago
- Yahoo
Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025
TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking place June 16–19 in Boston, MA. The company will be located at Booth #1645 within the Taiwan Pavilion, to showcase its innovative ENERGI Platform and provide a key update on its investigational Parkinson's disease (PD) therapy, ENERGI-F705PD, a first-in-class treatment with disease-modifying potential. Key Highlights: ENERGI-F705PD is a first-in-class, oral sustained-release therapy in development for Parkinson's disease, designed to address the underlying pathogenesis. Topline data from the Phase I trial in healthy subjects are anticipated in September 2025, following successful completion of recruitment. ENERGI-F705PD aims to combat the root causes of Parkinson's by reducing alpha-synuclein aggregation, enhancing antioxidant capacity, and boosting dopamine synthesis. "We are eager to present the exciting progress of our ENERGI-F705PD program at BIO International 2025," said Dr. Han-Min Chen, CEO of Energenesis Biomedical. "Parkinson's disease remains a challenging condition with significant unmet needs. Our approach focuses on restoring cellular energy and combating critical pathogenesis of PD, offering a potential disease-modifying solution for patients. We look forward to sharing our latest data and exploring potential partnerships that can accelerate the development of this important therapy." About ENERGI-F705PD ENERGI-F705PD is a novel small-molecule drug delivered in an oral sustained-release formulation. It is designed to enhance cellular ATP and antioxidant production by engaging the purine salvage, glycolysis, and pentose phosphate pathways. This multi-pronged mechanism of action directly addresses key pathological hallmarks of Parkinson's disease: Reduce and Prevent α-Synuclein Aggregation: Elevated ATP acts as a hydrotrope, helping prevent the intracellular aggregation of misfolded α-synuclein, a central pathogenic hallmark of PD. Increase Reducing Power (antioxidant): ENERGI-F705PD upregulates the pentose phosphate pathway (PPP), leading to increased NADPH production and enhanced cellular antioxidant defense. Increase Tyrosine Hydroxylase Expression/activity: By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD also enhances the expression and activity of tyrosine hydroxylase (TH), the key enzyme in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of PD patients. About Energenesis Biomedical Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that restore cellular energy and activate intrinsic repair mechanisms. By combining proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical aims to accelerate the development of treatments for unmet medical needs across various therapeutic areas, including neurodegenerative diseases, chronic wounds, and rare disorders. The company's robust pipeline includes: ENERGI-F705PD: Oral tablet for Parkinson's disease (Phase I) ENERGI-F703DFU: Gel for Diabetic foot ulcers (Phase III) ENERGI-F701: Tonic for Alopecia (Phase II completed) ENERGI-F703EB: Cream for Epidermolysis bullosa (EB), granted FDA Orphan Drug and Rare Pediatric Disease designation, and EMA orphan designation(Preparing for Phase II) For more information, please visit Contact: Business Development Team Email: partnership@ View original content: SOURCE ENERGENESIS BIOMEDICAL CO., LTD. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
